Patents by Inventor Marc Roller

Marc Roller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100278944
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Application
    Filed: May 4, 2009
    Publication date: November 4, 2010
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Publication number: 20100112098
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 5-caffeoylquinic acid (5-CQA) and total chlorogenic acids (tCGA) (5-CQA/tCGA) of between about 0.2 and 0.3. More preferably, the concentration of tCGA is greater than about 45% and the concentration of 5-CQA is less than about 10%. A preferred method of administration consists of administering between about 200 mg and about 1,000 mg per day, more preferably administering about 400 mg per day.
    Type: Application
    Filed: October 31, 2008
    Publication date: May 6, 2010
    Inventors: Benoit Lemaire, Sophie Lafay, Karine Nardon, Alvin Ibarra, Marc Roller, Jacques Dikansky
  • Publication number: 20100047372
    Abstract: A method of enhancing physical performance during exercise by administering an amount of a grape extract effective to treat a subject. A preferred grape extract comprises a concentration of flavanol monomers of greater than about 5% by weight, and more preferably within a range from about 12% by weight to about 50% by weight, and a concentration of flavanol dimers preferably greater than about 2% by weight, and more preferably within a range from about 6% by weight to about 20% by weight. The flavanol monomers preferably include catechin, epicatechin, epicatechin gallate, and gallic acid. The flavanol dimers preferably include procyanidin B1, procyanidin B2, procyanidin B3, procyanidin B4, and procyanidin B2-O-gallate.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 25, 2010
    Inventors: Benoit LEMAIRE, Sophie Lafay, Alvin Ibarra, Marc Roller, Jacques Dikansky
  • Publication number: 20090117214
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds G15, G13, nuzhenide, and oleoside dimethyl ester.
    Type: Application
    Filed: August 4, 2008
    Publication date: May 7, 2009
    Inventors: Kan He, Marc Roller, Antonie Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra